Related Experiment Video
Updated: Jan 26, 2026

Oxygenation-sensitive Cardiac MRI with Vasoactive Breathing Maneuvers for the Non-invasive Assessment of Coronary Microvascular Dysfunction
Published on: August 17, 2022
Do Statins Have a Positive Impact on Patients with Coronary Microvascular Dysfunction on Long-Term Clinical Outcome?
Wen-Hao Luo1,2, Yang Guo3, Jie-Wu Huang1
1The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China.
Insights
Statins significantly reduce major adverse cardiovascular events (MACE) in patients with coronary microvascular dysfunction (CMVD). This finding highlights statins as a key intervention for improving outcomes in this patient group.
Area of Science:
- Cardiology
- Vascular Medicine
- Pharmacology
Background:
- Coronary microvascular dysfunction (CMVD) is a significant contributor to cardiovascular events.
- Understanding therapeutic interventions for CMVD is crucial for patient management.
Purpose of the Study:
- To investigate the impact of statin therapy on major adverse cardiovascular events (MACE) in patients diagnosed with CMVD.
Main Methods:
- A retrospective analysis of 23,494 patients undergoing coronary angiography (CAG).
- Coronary microvascular dysfunction (CMVD) was assessed using the Thrombolysis in Myocardial Infarction, Myocardial Perfusion Grading (TMPG) method.
Main Results:
- Multivariate analysis identified statins as a significant protective factor against MACE in CMVD patients (HR, 0.33; P<0.001).
- Statins demonstrated efficacy in reducing MACE across various subgroups, including patients with a history of smoking, diabetes, hypertension, or combined hypertension and diabetes.
Conclusions:
- Statin therapy is associated with a significant reduction in MACE among patients with CMVD.
- These findings support the use of statins as a therapeutic strategy to mitigate cardiovascular risk in patients with CMVD.
Objectives:
To investigate the influence of statins on major adverse cardiovascular events (MACE) in patients with coronary microvascular dysfunction (CMVD).
Participants:
23,494 patients who received coronary angiography (CAG) were included. Thrombolysis in Myocardial Infarction, Myocardial Perfusion Grading (TMPG), a useful angiographic method, was used to evaluate CMVD.
Results:
Using multivariate analysis, NYHA III/IV (HR, 1.44; 95% CI, 1.03-2.01; P=0.031), PCI history (HR, 3.69; 95% CI, 2.57-5.31; P<0.001), TG (HR, 1.15; 95% CI, 1.06-1.26; P=0.001), creatinine (HR, 1.00; 95% CI, 1.00-1.01; P<0.001), cTnT (HR, 0.98; 95% CI, 0.96-0.99; P<0.001), heart rate (HR, 0.98; 95% CI, 0.97-0.99; P=0.001), β-blocker (HR, 0.68; 95% CI, 0.51-0.91; P=0.008), aspirin (HR, 0.38; 95% CI, 0.24-0.61; P<0.001), and statins (HR, 0.33; 95% CI, 0.19-0.60; P<0.001) significantly correlated with reduced MACE in CMVD patients. In subgroups analysis, statins decreased MACE overall (HR, 0.33; 95% CI, 0.19-0.59; P<0.001) and in CMVD patients with smoking history (HR, 0.64; 95% CI, 0.43-0.93; P=0.014), diabetes (HR,0.27; 95% CI,0.12-0.61; P=0.002), hypertension (HR, 0.10; 95% CI, 0.03-0.36; P=0.001), and hypertension and diabetes (HR, 0.09; 95% CI, 0.014-0.53; P=0.008).
Conclusion:
Statins could reduce MACE in patients with CMVD.
More Related Videos
Related Concept Videos
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Coronary Artery Disease III: Clinical Manifestations
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Predicting Reaction Outcomes
Acute Coronary Syndrome III: Diagnostic Studies
Impact of Groups on Groups

